Identity
- Security key
- 11596
- Ticker
- ALMS
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2024-06-28
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- ALMS
Detail
Enriched 2026-08-14 20:47
- Market cap
- $3,257,420,089
- Shares outstanding (class)
- 123,432,072
- Shares outstanding (weighted)
- 127,491,980
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 227
- Location
- SOUTH SAN FRANCISCO, CA
- Homepage
- https://www.alumis.com
- Description
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.